Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study.
Twenty-four patients with recurrent or metastatic cervical cancer were treated with vindesine (VDS) (2 mg/m2) on 2 subsequent days per week. Twenty patients were evaluable for response. There were six partial responses (30%) and no complete responses. The median remission duration was 6.5 months. The results indicate that VDS is active in the treatment of cervical cancer. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. VDS should be considered in the treatment planning of combination chemotherapy for cervical cancer.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014751:Vindesine / Q000009:adverse effects / Q000627:therapeutic use*
D014751:Vindesine